Particle.news
Download on the App Store

Cohere Buys Reliant AI to Push Into Life Sciences

The move brings domain expertise that can speed Cohere’s push to offer secure AI for tightly regulated health care.

Overview

  • Cohere, which announced the deal Tuesday, is acquiring Reliant AI to grow in biopharma and other regulated markets.
  • Reliant builds tools that help drug teams sift medical studies, review clinical trials and rank drug candidates for market fit, with customers like GSK, Ipsen, Kyowa Kirin and OMass.
  • Reliant’s co-founders, Karl Moritz Hermann and Marc Bellemare, will become vice-presidents at Cohere, and about 30 to 35 employees will join the company.
  • Cohere will fold Reliant’s models, data and clients into North, its platform for building task-focused AI agents that companies can run on their own hardware.
  • The purchase lands as Cohere pursues a planned merger with Germany’s Aleph Alpha that still requires approvals, and the Reliant deal’s financial terms were not disclosed.